FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Mapping the hidden rules of a key immune sensor
Large-scale microbiome study identifies robust colorectal cancer signature
Light-based imaging offers hope in improving thyroid cancer diagnosis while reducing surgeries
Rare combined liver cancer highlights challenges in diagnosis and treatment
Scientists uncover how ovarian cancer resists chemotherapy — and how to reverse it
TRAIL-R2 silencing linked to more aggressive breast cancer
Socioeconomic challenges colour patients’ lung cancer screening experience
Fat tissue could explain triple negative breast cancer spread - and point to treatments
Fertility preservation care is still out of reach for many girls and young women with cancer, a Nursing Review finds
Changes in AI mammogram risk scores over time help predict future breast cancer
Unlocking disease-linked protein changes using AI